Unicycive Therapeutics, Inc. (UNCY) is a Biotechnology company in the Healthcare sector, currently trading at $6.94. It has a SharesGrow Score of 43/100, indicating a mixed investment profile with 1 out of 7 criteria passed.
Valuation: UNCY trades at a trailing Price-to-Earnings (P/E) of -39.7 (S&P 500 average ~25).
Net income is $27M (loss), growing at -20.5%/yr. Net profit margin is 0% (thin). Gross margin is 100% (+0.7 pp trend).
Balance sheet: total debt is $117,000 against $30M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 2.59 (strong liquidity). Debt-to-assets is 0.2%. Total assets: $49M.
Analyst outlook: 6 / 6 analysts rate UNCY as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 46/100 (Partial), Future 100/100 (Pass), Income ?/100 (Fail).
